Differences in the cellular processing of AspB10 human insulin compared with human insulin and LysB28ProB29 human insulin.

[1]  J. Zimmermann,et al.  12-Month Chronic Toxicity Study of LY275585 (Human Insulin Analog) Administered Subcutaneously to Fischer 344 Rats , 1997 .

[2]  L. Slieker,et al.  Modifications in the B10 and B26–30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor , 1997, Diabetologia.

[3]  W. Duckworth,et al.  The significance of intracellular insulin to insulin action. , 1997, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.

[4]  L. Vignati,et al.  Reduction of Postprandial Hyperglycemia and Frequency of Hypoglycemia in IDDM Patients on Insulin-Analog Treatment , 1997, Diabetes.

[5]  H. Klein,et al.  Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. , 1996, The Biochemical journal.

[6]  T. Jones,et al.  General pharmacology of insulin lispro in animals. , 1996, Arzneimittel-Forschung.

[7]  P. Brunetti,et al.  Improved Postprandial Metabolic Control After Subcutaneous Injection of a Short-Acting Insulin Analog in IDDM of Short Duration With Residual Pancreatic β-Cell Function , 1995, Diabetes Care.

[8]  D. Howey,et al.  [Lys(B28), Pro(B29)]‐human insulin: Effect of injection time on postprandial glycemia , 1995, Clinical pharmacology and therapy.

[9]  J. Betz.  Fast-Acting Human Insulin Analogs: A Promising Innovation in Diabetes Care , 1995, The Diabetes educator.

[10]  Chance Re,et al.  Improving Insulin Therapy: Achievements and Challenges , 1994 .

[11]  D. Howey,et al.  [Lys(B28), Pro(B29)]-Human Insulin: A Rapidly Absorbed Analogue of Human Insulin , 1994, Diabetes.

[12]  D. Leroith,et al.  Current Directions in Insulin-Like Growth Factor Research , 2013, Advances in Experimental Medicine and Biology.

[13]  L. Slieker,et al.  Insulin and IGF-I analogs: novel approaches to improved insulin pharmacokinetics. , 1993, Advances in experimental medicine and biology.

[14]  K. Drejer.  The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake. , 1992, Diabetes/metabolism reviews.

[15]  B H Frank,et al.  Altering the association properties of insulin by amino acid replacement. , 1992, Protein engineering.

[16]  D. Brems,et al.  Synthesis of a Fast-Acting Insulin Based on Structural Homology with Insulin-Like Growth Factor I, , 1992 .

[17]  D R Owens,et al.  Monomeric Insulins and Their Experimental and Clinical Implications , 1990, Diabetes Care.

[18]  W. Duckworth,et al.  High performance liquid chromatographic analysis of insulin degradation by rat skeletal muscle insulin protease. , 1986, Endocrinology.

[19]  W. Duckworth,et al.  Selective effects of inhibitors of hormone processing on insulin action in isolated hepatocytes. , 1984, Endocrinology.

[20]  B. Frank,et al.  High-performance liquid chromatographic preparation of single-site carrier-free pancreatic polypeptide hormone radiotracers. , 1983, Journal of chromatography.

[21]  W. Duckworth,et al.  Receptor Binding Properties of Monoiodotyrosyl Insulin Isomers Purified by High Performance Liquid Chromatography , 1983, Diabetes.

[22]  J. Massagué,et al.  The high affinity insulin receptor mediates growth stimulation in rat hepatoma cells. , 1982, The Journal of biological chemistry.

[23]  B. Draznin,et al.  Inhibition of intracellular proteolysis by insulin in isolated rat hepatocytes. Possible role of internalized hormone. , 1982, The Journal of biological chemistry.

[24]  D. Steiner,et al.  Binding and degradation of 125I-insulin by rat hepatocytes. , 1975, The Journal of biological chemistry.

[25]  W. Duckworth,et al.  Purification of insulin-specific protease by affinity chromatography. , 1972, Proceedings of the National Academy of Sciences of the United States of America.